Comparison of immediate vs deferred cytoreductive nephrectomy in patients with synchronous metastatic renal cell carcinoma receiving sunitinib: The surtime randomized clinical trial

Published on Feb 1, 2019in JAMA Oncology24.799
· DOI :10.1001/JAMAONCOL.2018.5543
Axel Bex54
Estimated H-index: 54
(NKI-AVL: Netherlands Cancer Institute),
Peter F.A. Mulders79
Estimated H-index: 79
(Radboud University Nijmegen)
+ 17 AuthorsJohn B. A. G. Haanen77
Estimated H-index: 77
(NKI-AVL: Netherlands Cancer Institute)
Sources
Abstract
Importance In clinical practice, patients with primary metastatic renal cell carcinoma (mRCC) have been offered cytoreductive nephrectomy (CN) followed by targeted therapy, but the optimal sequence of surgery and systemic therapy is unknown. Objective To examine whether a period of sunitinib therapy before CN improves outcome compared with immediate CN followed by sunitinib. Design, Setting, and Participants This randomized clinical trial began as a phase 3 trial on July 14, 2010, and continued until March 24, 2016, with a median follow-up of 3.3 years and a clinical cutoff date for this report of May 5, 2017. Patients with mRCC of clear cell subtype, resectable primary tumor, and 3 or fewer surgical risk factors were studied. Interventions Immediate CN followed by sunitinib therapy vs treatment with 3 cycles of sunitinib followed by CN in the absence of progression followed by sunitinib therapy. Main Outcomes and Measures Progression-free survival was the primary end point, which needed a sample size of 458 patients. Because of poor accrual, the independent data monitoring committee endorsed reporting the intention-to-treat 28-week progression-free rate (PFR) instead. Overall survival (OS), adverse events, and postoperative progression were secondary end points. Results The study closed after 5.7 years with 99 patients (80 men and 19 women; mean [SD] age, 60 [8.5] years). The 28-week PFR was 42% in the immediate CN arm (n = 50) and 43% in the deferred CN arm (n = 49) (P = .61). The intention-to-treat OS hazard ratio of deferred vs immediate CN was 0.57 (95% CI, 0.34-0.95;P = .03), with a median OS of 32.4 months (95% CI, 14.5-65.3 months) in the deferred CN arm and 15.0 months (95% CI, 9.3-29.5 months) in the immediate CN arm. In the deferred CN arm, 48 of 49 patients (98%; 95% CI, 89%-100%) received sunitinib vs 40 of 50 (80%; 95% CI, 67%-89%) in the immediate arm. Systemic progression before planned CN in the deferred CN arm resulted in a per-protocol recommendation against nephrectomy in 14 patients (29%; 95% CI, 18%-43%). Conclusions and Relevance Deferred CN did not improve the 28-week PFR. With the deferred approach, more patients received sunitinib and OS results were higher. Pretreatment with sunitinib may identify patients with inherent resistance to systemic therapy before planned CN. This evidence complements recent data from randomized clinical trials to inform treatment decisions in patients with primary clear cell mRCC requiring sunitinib. Trial Registration ClinicalTrials.gov identifier:NCT01099423
📖 Papers frequently viewed together
969 Citations
790 Citations
265 Citations
References30
Newest
#1Arnaud Mejean (Paris V: Paris Descartes University)H-Index: 61
#2A. Ravaud (Paris V: Paris Descartes University)H-Index: 4
Last. B. Escudier (Paris V: Paris Descartes University)H-Index: 11
view all 29 authors...
Abstract Background Cytoreductive nephrectomy has been the standard of care in metastatic renal-cell carcinoma for 20 years, supported by randomized trials and large, retrospective studies. However, the efficacy of targeted therapies has challenged this standard. We assessed the role of nephrectomy in patients with metastatic renal-cell carcinoma who were receiving targeted therapies. Methods In this phase 3 trial, we randomly assigned, in a 1:1 ratio, patients with confirmed metastatic clear-ce...
329 CitationsSource
#1Samra Turajlic (The Royal Marsden NHS Foundation Trust)H-Index: 30
#2Hang Xu (Francis Crick Institute)H-Index: 10
Last. PeaceH-Index: 1
view all 50 authors...
Clear-cell renal cell carcinoma (ccRCC) exhibits a broad range of metastatic phenotypes that have not been systematically studied to date. Here, we analyzed 575 primary and 335 metastatic biopsies across 100 patients with metastatic ccRCC, including two cases sampledat post-mortem. Metastatic competence was afforded by chromosome complexity, and we identify 9p loss as a highly selected event driving metastasis and ccRCC-related mortality (p = 0.0014). Distinct patterns of metastatic disseminatio...
304 CitationsSource
#1Axel Bex (NKI-AVL: Netherlands Cancer Institute)H-Index: 54
#2Börje Ljungberg (Umeå University)H-Index: 70
Last. Thomas Powles (QMUL: Queen Mary University of London)H-Index: 84
view all 4 authors...
Patient summary: After the introduction of systemic targeted therapies, the use of nephrectomy in patients with metastatic renal cell carcinoma has declined. Currently, systemic therapy is offered ...
25 CitationsSource
#1Thomas Powles (QMUL: Queen Mary University of London)H-Index: 84
#2Naveed Sarwar (Imperial College London)H-Index: 15
Last. Simon J. Crabb (University of Southampton)H-Index: 30
view all 23 authors...
Importance The role of cytoreductive nephrectomy in patients with metastatic renal cancer in the era of targeted therapy is uncertain. Objective To establish the safety and efficacy of upfront pazopanib therapy prior to cytoreductive nephrectomy in previously untreated patients with metastatic clear cell renal cancer. Design, Setting, and Participants Single-arm phase 2 study of 104 previously untreated patients with metastatic clear cell renal cancer recruited between June 2008 and October 2012...
49 CitationsSource
#1Nawar HannaH-Index: 12
#2Maxine Sun (Brigham and Women's Hospital)H-Index: 74
Last. Toni K. Choueiri (Harvard University)H-Index: 116
view all 9 authors...
PurposeThe role of cytoreductive nephrectomy (CN) in metastatic renal cell carcinoma (mRCC) has become unclear since the introduction of targeted therapies (TT). We sought to evaluate contemporary utilization rates of CN and to examine the survival benefit of CN compared with non-CN patients treated with TT.MethodsWe used the National Cancer Data Base to identify patients with clinical mRCC treated with TT between 2006 and 2013. The intervention of interest was CN. Multivariable logistic regress...
121 CitationsSource
#1Christopher J.D. Wallis (Sunnybrook Health Sciences Centre)H-Index: 24
#2Georg A. Bjarnason (Sunnybrook Health Sciences Centre)H-Index: 18
Last. Raj Satkunasivam (Sunnybrook Health Sciences Centre)H-Index: 17
view all 9 authors...
Objective To determine the effect of disseminated cancer on perioperative outcomes following radical nephrectomy. Methods We conducted a retrospective cohort study of patients undergoing radical nephrectomy for kidney cancer from 2005 to 2014 using the American College of Surgeons National Surgical Quality Improvement Program, a multi-institutional prospective registry that captures perioperative surgical complications. Patients were stratified according to the presence (n = 657) or absence (n =...
11 CitationsSource
#1Nishant Patel (UCSD: University of California, San Diego)H-Index: 16
#2Jason Woo (UCSD: University of California, San Diego)H-Index: 6
Last. Ithaar H. Derweesh (UCSD: University of California, San Diego)H-Index: 43
view all 14 authors...
To compare surgical complications and tyrosine kinase inhibitor (TKI)-toxicities in patients who underwent primary cytoreductive nephrectomy (CN) followed by adjuvant TKI therapy versus those who underwent neoadjuvant TKI therapy prior to planned CN for metastatic renal cell carcinoma (mRCC).Two-center retrospective analysis. Sixty-one mRCC patients underwent TKI therapy with sunitinib between July 2007 to January 2014. Patients were divided into three groups: primary CN followed by adjuvant TKI...
9 Citations
#1Benjamin L. Jackson (St. Vincent's Health System)H-Index: 2
#2Sarah FowlerH-Index: 9
Last. S.T Williams (Royal Derby Hospital)H-Index: 10
view all 3 authors...
Objectives To define the perioperative morbidity and 30-day mortality of cytoreductive nephrectomy (CN) using the British Association of Urological Surgeons (BAUS) nephrectomy dataset for 2012, the first year of public reporting of individual surgeon outcomes in the UK. Patients and Methods All nephrectomies recorded in the database in 2012 were analysed, and cytoreductive cases identified. Outcome measures were: blood loss of >1000 mL, transfusion requirement, intra- and postoperative complicat...
18 CitationsSource
#1Daniel Y.C. Heng (U of C: University of Calgary)H-Index: 16
#2J. Connor WellsH-Index: 11
Last. Toni K. Choueiri (Harvard University)H-Index: 116
view all 20 authors...
Abstract Background The benefit of cytoreductive nephrectomy (CN) for overall survival (OS) is unclear in patients with synchronous metastatic renal cell carcinoma (mRCC) in the era of targeted therapy. Objective To determine OS benefit of CN compared with no CN in mRCC patients treated with targeted therapies. Design, setting, and participants Retrospective data from patients with synchronous mRCC ( n =1658) from the International Metastatic Renal Cell Carcinoma Database Consortium (IMDC) were ...
265 CitationsSource
#1Lauren C. Harshman (Stanford University)H-Index: 27
#2R. James Yu (Stanford University)H-Index: 1
Last. Benjamin I. Chung (Stanford University)H-Index: 27
view all 6 authors...
Abstract Background Tyrosine kinase inhibitors (TKI) have dramatically changed the management paradigm of advanced renal cell carcinoma (RCC) and are increasingly being used preoperatively to achieve cytoreduction. Objective To review our case series of post-TKI surgical procedures to add to the current perioperative efficacy and complication profile. Materials and methods Between October 2006 and February 2010, 14 cytoreductive nephrectomies, radical nephrectomies, and metastectomies were perfo...
42 CitationsSource
Cited By140
Newest
#1Sai Krishnaraya Doppalapudi (RU: Rutgers University)H-Index: 1
#2Zev Leopold (RU: Rutgers University)H-Index: 1
Last. Eric A. Singer (RU: Rutgers University)H-Index: 17
view all 0 authors...
Patients with advanced or malignant renal cell carcinoma at the time of diagnosis have historically had a poor prognosis. Immunonologic agents have significantly altered the therapeutic landscape and clinical outcomes of these patients. In this review, we highlight recent and upcoming clinical trials investigating the role of immunotherapies in clear cell RCC. In particular, we emphasize immunotherapy-based combinations, including immune checkpoint inhibitor (ICI) combinations, neoadjuvant, and ...
Source
#1Eduard Roussel (Katholieke Universiteit Leuven)H-Index: 3
#2Benoit Beuselinck (Katholieke Universiteit Leuven)H-Index: 25
Last. Maarten Albersen (Katholieke Universiteit Leuven)H-Index: 26
view all 3 authors...
Take Home Message null null Cytoreductive nephrectomy makes way for more effective systemic treatments in the current mRCC treatment paradigm, as disease volume and the number of IMDC risk factors increase. Careful patient selection for upfront or deferred cytoreductive nephrectomy based on these criteria remains key.
Source
#1Ashanda Rosetta Patrice Esdaille (UW: University of Wisconsin-Madison)
#2E. Jason Abel (UW: University of Wisconsin-Madison)H-Index: 18
Source
#1Andrew W. Silagy (MSK: Memorial Sloan Kettering Cancer Center)H-Index: 4
#2Ritesh Kotecha (MSK: Memorial Sloan Kettering Cancer Center)H-Index: 9
Last. Sujata Patil (MSK: Memorial Sloan Kettering Cancer Center)H-Index: 65
view all 15 authors...
BACKGROUND Systemic responses to cytoreductive nephrectomy (CN) in the management of metastatic renal cell carcinoma (mRCC) are variable and difficult to anticipate. The authors aimed to determine the association of CN with modifiable International Metastatic Renal Cell Carcinoma Database Consortium (IMDC) risk factors and oncological outcomes. METHODS Consecutive patients with mRCC referred for potential CN (2009-2019) were reviewed. The primary outcome was overall survival (OS); variables of i...
Source
#1Tomoyuki HishidaH-Index: 33
#2Kyohei MasaiH-Index: 8
Last. Hisao Asamura (Keio: Keio University)H-Index: 86
view all 5 authors...
Debulking surgery, also called cytoreductive surgery, is a resection of the tumor as much as possible and an intended incomplete resection for unresectable malignant tumors. Since the most important principle in surgical oncology is complete R0 resection, debulking surgery goes against the basic principle and obscures the concept of operability. However, debulking surgery has been advocated for various types of advanced malignant tumors, including gynecological cancers, urological cancers, gastr...
Source
#1Hiroki IshiharaH-Index: 10
#2Toshio TakagiH-Index: 21
Last. Kazunari TanabeH-Index: 54
view all 6 authors...
Source
#1Lauri Laru (OUH: Oulu University Hospital)
#2Hanna Ronkainen (OUH: Oulu University Hospital)H-Index: 7
Last. Markku H. Vaarala (OUH: Oulu University Hospital)H-Index: 22
view all 4 authors...
BACKGROUND The purpose of this study was to evaluate the effects of cytoreductive nephrectomy (CN) and metastasectomies on the survival of patients with synchronous metastatic renal cell cancer (mRCC) using real-life, population-based national dataset. METHODS Nationwide data, including all cases of synchronous mRCC in Finland diagnosed on a 6-year timeframe, based on the Finnish Cancer Registry and complemented with patient records from the treating hospitals, were analyzed. Patients with Easte...
Source
#1Arnaud MejeanH-Index: 61
#2Alain Ravaud (University of Bordeaux)H-Index: 77
Last. Laurent GuyH-Index: 26
view all 24 authors...
Abstract null null Background null The CARMENA trial in patients with metastatic renal cell carcinoma (mRCC) demonstrated that treatment with sunitinib alone was noninferior to cytoreductive nephrectomy (CN) followed by sunitinib (nephrectomy–sunitinib). null null null Objective null The objective of this study was to provide updated overall survival (OS) outcomes of CARMENA and assess whether some subgroups may still benefit from upfront CN. null null null Design, setting, and participants null...
1 CitationsSource
The aim of this article is to summarise key studies relevant to Part 2 of the FRCS (Urol) examination.
Source
#1Yudai IshiyamaH-Index: 2
#2Tsunenori KondoH-Index: 23
Last. Kazunari TanabeH-Index: 54
view all 6 authors...
OBJECTIVES To evaluate the outcomes of Japanese patients with renal cell carcinoma undergoing surgery for tumor thrombus invading the right atrium. METHODS We retrospectively evaluated 23 patients who underwent extracorporeal circulation-assisted surgery at two institutions. Perioperative outcomes and survival rates were evaluated and compared between two groups of patients, which were set according to the use or not of deep hypothermic circulatory arrest. Data on systemic treatments were assess...
Source